Liu Jiayin, Li Dan, Han Jing, Zhang Yin, Zhang Xue, Fan Zhisong, Feng Li, Wang Long, Jin Hui, Zuo Jing, Wang Yudong
Department of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Inspection Department, Shijiazhuang Institue for Food and Drug Control, Shijiazhuang, Hebei, China.
Front Oncol. 2023 Mar 10;13:1091669. doi: 10.3389/fonc.2023.1091669. eCollection 2023.
The microsatellite stability(MSS) subtype of Colorectal Cancer(CRC) represents approximately 95% of mCRC cases. Immunotherapy was not as encouraging as the data for MSS mCRC cancer. We report the treatment of a series of patients with extrahepatic metastasis of MSS colorectal cancer, which can provide reference and guidance for the treatment of non-hepatic metastasis of MSS colorectal.
This report describes 8 typical cases of successful MSS treatment with lung metastases of CRC. We systematically reviewed the clinical data and detailed medical history of one of these patients with extrahepatic metastasis from MSS colorectal cancer, and reviewed the literature to analyze and discuss the related epidemiological features, mechanisms and recent research findings of the special subgroup of the population.
Although MSS colon rectal cancer is still known as a cold tumor in the industry, immunotherapy combined with multi-targeted anti-vascular tyrosine kinase inhibitors had brought clinical benefits to patients with non-hepatic metastases from MSS colorectal cancer.
结直肠癌（CRC）的微卫星稳定（MSS）亚型约占转移性结直肠癌（mCRC）病例的95%。免疫疗法的效果不如MSS mCRC的相关数据那么令人鼓舞。我们报告了一系列MSS结直肠癌肝外转移患者的治疗情况，可为MSS结直肠癌非肝转移的治疗提供参考和指导。
本报告描述了8例成功治疗MSS CRC肺转移的典型病例。我们系统回顾了其中1例MSS结直肠癌肝外转移患者的临床资料和详细病史，并查阅文献，分析讨论该特殊人群亚组的相关流行病学特征、机制及最新研究发现。
尽管MSS结肠癌在业内仍被称为冷肿瘤，但免疫疗法联合多靶点抗血管酪氨酸激酶抑制剂已为MSS结直肠癌非肝转移患者带来了临床获益。
